Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on treating cancer with Veyonda®, its lead drug candidate.

Veyonda® is a dual-acting oncotoxic and immuno-oncology drug designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapy, radiotherapy and immuno-oncology drugs. The drug acts by harnessing the body’s immune system to inflict damage oncancer cells in the body and has shown promise in treating a broad spectrum of cancers.

Noxopharm also has an active research and development (R&D) program for additional drug candidates and is the major shareholder of US biotechnology company Nyrada Inc. (ASX:NYR). 

Media Releases

Latest Company News


Oct 2020 01:05 PM
Noxopharm (ASX:NOX) announces ..
09 Oct 2020 - Noxopharm Limited (ASX:NOX) Chief Medical Officer Dr Gisela Mautner provides an update on the company's lead drug candidate Veyonda in its DARRT program and discusses a new trial program for COVID-19.

Contact Information